Mylan Profit Misses Estimates as EpiPen Sales Decline

Updated on
  • Allergy shot’s division posts 4% decline in quarterly sales
  • Company says its business model isn’t based on price hikes

Mylan NV’s third-quarter profit missed analysts’ estimates as the drugmaker sold fewer EpiPen emergency allergy shots ahead of a cheaper version of the product that could be launched before next year.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.